TARA

Protara Therapeutics, Inc. [TARA] Stock Forecast

Q: What is Protara Therapeutics, Inc. stock symbol ?

Protara Therapeutics, Inc. is a US stock, located in New york of Ny and trading under the symbol TARA

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

TARA Stock Summary

Does not have any significance market cap ($19.49M)

TARA has less than 1 year of cash runway

An RSI reading of 30 or below indicates an oversold or undervalued condition.

Top 10 Correlated ETFs

TARA

Top 10 Correlated Stocks

TARA

In the News

07:30 29 Sep 2023 TARA

Protara Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference

NEW YORK, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will present at the H.C. Wainwright 25th Annual Global Investment Conference on Monday, September 11, 2023, at 9:30 am ET in New York.

08:00 29 Sep 2023 TARA

Protara Therapeutics to Participate in Upcoming Investor Conferences

NEW YORK, March 01, 2023 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will participate in the following upcoming investor conferences:

08:00 29 Sep 2023 TARA

Protara Therapeutics to Present at the Guggenheim Healthcare Talks Oncology Day

NEW YORK, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will participate in a fireside chat at the Guggenheim Healthcare Talks Oncology Day on Thursday, February 9, 2023 at 11:20 am ET in New York, New York.

11:00 29 Sep 2023 TARA

Insider Buying 2022: 15 Stocks to Bet On Despite the Bear Market

In October 2021, I made a big call on Longeveron (NASDAQ: LGVN ) stock, a biotech firm working on a promising Alzheimer's therapy.

07:14 29 Sep 2023 TARA

Executives Buy Around $35M Of 4 Penny Stocks: Nextdoor, GreenLight Biosciences And More

The Dow Jones jumped by around 150 points on Monday. Investors, meanwhile, focused on some notable insider trades.

11:17 29 Sep 2023 TARA

Can Protara Therapeutics (TARA) Climb 680% to Reach the Level Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 680.4% in Protara Therapeutics (TARA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

08:00 29 Sep 2023 TARA

Protara Therapeutics to Participate in Upcoming Investor Conferences

NEW YORK, March 02, 2022 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will participate in fireside chats at two upcoming virtual conferences:

08:00 29 Sep 2023 TARA

Protara Therapeutics to Present at the H.C. Wainwright BioConnect Virtual Conference

NEW YORK, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced that management will present at the H.C. Wainwright BioConnect Virtual Conference being held from January 10-13, 2022.

05:57 29 Sep 2023 TARA

TARA Stock: Why The Price Increased This Past Week

The stock price of Protara Therapeutics Inc (NASDAQ: TARA) increased by over 5% during intraday trading. This is why it happened.

10:26 29 Sep 2023 TARA

Biopharma Stock Skyrockets on FDA Approval

Biopharmaceutical stock Protara Therapeutics Inc (NASDAQ:TARA) is surging today, up 11.9% to trade at $7.55 at last check.

TARA Financial details

Company Rating

Neutral

Market Cap

19.49M

Income

-65.92M

Revenue

Book val./share

7.54

Cash/share

7.11

Dividend

Dividend %

Employees

Optionable

Shortable

Yes

Earnings

01 Nov 2023

P/E

-0.29

Forward P/E

PEG

-0.07

P/S

P/B

0.22

P/C

0.23

P/FCF

-0.58

Quick Ratio

16.36

Current Ratio

17.09

Debt / Equity

0.07

LT Debt / Equity

0.06

EPS (TTM)

-5.85

EPS next Y

EPS next Q

EPS this Y

37.14%

EPS next Y

EPS next 5Y

EPS last 5Y

Revenue last 5Y

Revenue Q/Q

EPS Q/Q

35.14%

SMA20

SMA50

-33.33%

SMA100

-33.33%

Inst Own

46.5%

Inst Trans

0.96%

ROA

-69%

ROE

-63%

ROC

-0.1%

Gross Margin

Oper. Margin

Profit Margin

Payout

Shs Outstand

11.33M

Shs Float

6.27M

Target Price

52W Range

1.62-4.18

52W High

-58.38%

52W Low

+66.5%

RSI

Rel Volume

0.3

Avg Volume

27.47K

Volume

8.36K

Perf Week

-9.02%

Perf Month

-26.97%

Perf Quarter

-43.75%

Perf Half Y

-48.93%

Beta

1.49908

Volatility

0.03%, 0.22%

Prev Close

-0.89%

Price

1.665

Change

-2.63%

TARA Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31
Revenue per share	0	0	0	0	0
Net income per share	-9.93	-2.52	-4.63	-4.2	-5.76
Operating cash flow per share	-9.07	-2.68	-3.24	-3.07	-2.35
Free cash flow per share	-9.12	-2.68	-3.36	-3.12	-2.36
Cash per share	8.54	1.06	23.31	8.12	7.49
Book value per share	7.98	1.09	27.54	14.41	9.07
Tangible book value per share	7.98	1.09	23.46	11.79	9.07
Share holders equity per share	7.98	1.09	27.54	14.41	9.07
Interest debt per share	0	0	0.15	0.64	0.67
Market cap	232.49M	95.84M	175.13M	75.82M	30.18M
Enterprise value	213.12M	89.66M	7.62M	47.33M	12.43M
P/E ratio	-9.14	-6.51	-5.23	-1.61	-0.47
Price to sales ratio	0	0	0	0	0
POCF ratio	-10.01	-6.13	-7.48	-2.2	-1.14
PFCF ratio	-9.96	-6.12	-7.21	-2.16	-1.14
P/B Ratio	11.37	14.99	0.88	0.47	0.3
PTB ratio	11.37	14.99	0.88	0.47	0.3
EV to sales	0	0	0	0	0
Enterprise value over EBITDA	-8.07	-5.88	-0.22	-1	-1.55
EV to operating cash flow	-9.17	-5.73	-0.33	-1.37	-0.47
EV to free cash flow	-9.13	-5.72	-0.31	-1.35	-0.47
Earnings yield	-0.11	-0.15	-0.19	-0.62	-2.15
Free cash flow yield	-0.1	-0.16	-0.14	-0.46	-0.88
Debt to equity	0	0	0.01	0.04	0.06
Debt to assets	0	0	0.01	0.04	0.06
Net debt to EBITDA	0.73	0.41	4.89	0.6	2.21
Current ratio	7.55	11.96	58.13	21.66	15.01
Interest coverage	0	0	0	0	-58.98
Income quality	1.12	1.04	0.69	0.73	0.4
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0	0	0	0	0
Research and developement to revenue	0	0	0	0	0
Intangibles to total assets	0	0	0.15	0.17	0
Capex to operating cash flow	0.01	0	0.04	0.02	0
Capex to revenue	0	0	0	0	0
Capex to depreciation	-1.03	-0.06	-4.51	-5.09	-0.48
Stock based compensation to revenue	0	0	0	0	0
Graham number	42.25	7.88	53.58	36.89	34.27
ROIC	-1.54	-2.34	-0.17	-0.27	-0.57
Return on tangible assets	-1.08	-2.11	-0.19	-0.33	-0.57
Graham Net	7.34	0.96	22.77	7.27	6.58
Working capital	20.16M	6.39M	166.52M	88.81M	80.41M
Tangible asset value	20.44M	6.39M	169.73M	132.4M	102.08M
Net current asset value	20.16M	6.39M	165.52M	82.43M	74.94M
Invested capital	0	0	0.01	0.04	0.06
Average receivables	0	0	0	317K	560K
Average payables	366K	352K	588.5K	934K	1.27M
Average inventory	0	0	0	607.5K	1.19M
Days sales outstanding	0	0	0	0	0
Days payables outstanding	0	0	0	0	0
Days of inventory on hand	0	0	0	0	0
Receivables turnover	0	0	0	0	0
Payables turnover	0	0	0	0	0
Inventory turnover	0	0	0	0	0
ROE	-1.24	-2.3	-0.17	-0.29	-0.63
Capex per share	-0.05	0	-0.12	-0.05	-0.01

Quarterly Fundamentals Overview

Last date of statement is 2023-06-30 for Q2

Metric	2022-06-30	2022-09-30	2022-12-31	2023-03-31	2023-06-30
Revenue per share	0	0	0	0	0
Net income per share	-0.73	-0.66	-3.45	-0.74	-1
Operating cash flow per share	-0.46	-0.47	-0.45	-1.14	-0.83
Free cash flow per share	-0.46	-0.48	-0.45	-1.14	-0.83
Cash per share	8.75	8.55	7.49	7.66	7.11
Book value per share	12.92	12.35	9.06	8.38	7.54
Tangible book value per share	10.3	9.73	9.06	8.38	7.54
Share holders equity per share	12.92	12.35	9.06	8.38	7.54
Interest debt per share	0.64	0.61	0.58	0.48	0.52
Market cap	32.98M	33.35M	30.2M	35.38M	27.03M
Enterprise value	5.98M	-7.55M	12.45M	20.51M	-1.02M
P/E ratio	-1.01	-1.13	-0.19	-1.06	-0.6
Price to sales ratio	0	0	0	0	0
POCF ratio	-6.44	-6.24	-6.01	-2.75	-2.87
PFCF ratio	-6.41	-6.14	-6	-2.74	-2.87
P/B Ratio	0.23	0.24	0.3	0.37	0.32
PTB ratio	0.23	0.24	0.3	0.37	0.32
EV to sales	0	0	0	0	0
Enterprise value over EBITDA	-0.73	1.19	0.64	-2.11	0.08
EV to operating cash flow	-1.17	1.41	-2.48	-1.59	0.11
EV to free cash flow	-1.16	1.39	-2.47	-1.59	0.11
Earnings yield	-0.25	-0.22	-1.29	-0.24	-0.42
Free cash flow yield	-0.16	-0.16	-0.17	-0.36	-0.35
Debt to equity	0.05	0.05	0.06	0.07	0.07
Debt to assets	0.04	0.04	0.06	0.06	0.06
Net debt to EBITDA	3.32	6.46	-0.91	1.53	2.32
Current ratio	28.94	26.59	15.01	14.76	17.09
Interest coverage	-25.16	-29.1	191.35	14.17	0
Income quality	0.6	0.7	0.13	1.42	0.83
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0	0	0	0	0
Research and developement to revenue	0	0	0	0	0
Intangibles to total assets	0.19	0.2	0	0	0
Capex to operating cash flow	0	0.02	0	0	0
Capex to revenue	0	0	0	0	0
Capex to depreciation	-0.38	-0.08	0.01	-0.08	-0.03
Stock based compensation to revenue	0	0	0	0	0
Graham number	14.55	13.52	26.51	11.81	13.01
ROIC	-0.05	-0.05	0.18	-0.08	-0.12
Return on tangible assets	-0.07	-0.06	-0.34	-0.08	-0.12
Graham Net	7.92	7.74	6.58	6.64	6.41
Working capital	97.6M	94.96M	80.41M	88.21M	79.33M
Tangible asset value	115.94M	109.66M	102.08M	94.77M	85.23M
Net current asset value	91.67M	89.25M	74.94M	82.98M	74.35M
Invested capital	0.05	0.05	0.06	0.07	0.07
Average receivables	507.5K	433.5K	433K	488.5K	417.5K
Average payables	466.5K	424K	1.02M	2.83M	2.97M
Average inventory	1.04M	-243.5K	581.5K	336K	1.53M
Days sales outstanding	0	0	0	0	0
Days payables outstanding	0	0	0	0	0
Days of inventory on hand	0	0	0	0	0
Receivables turnover	0	0	0	0	0
Payables turnover	0	0	0	0	0
Inventory turnover	0	0	0	0	0
ROE	-0.06	-0.05	-0.38	-0.09	-0.13
Capex per share	0	-0.01	0	0	0

TARA Frequently Asked Questions

What is Protara Therapeutics, Inc. stock symbol ?

Protara Therapeutics, Inc. is a US stock , located in New york of Ny and trading under the symbol TARA

What is Protara Therapeutics, Inc. stock quote today ?

Protara Therapeutics, Inc. stock price is $1.665 today.

Is Protara Therapeutics, Inc. stock public?

Yes, Protara Therapeutics, Inc. is a publicly traded company.

Something similar

Top by Market Cap

Top Correlated ETFs

Top Correlated Stocks

Similar Market Cap

Company Profile

Volume Average 27.47K
Market Capitalization 19.49M
Employee 25
CEO Mr. Jesse Shefferman
Headquarters New York,NY,US
IPO Date 2014-10-22
Website https://www.protaratx.com

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May 2020. Protara Therapeutics, Inc. is headquartered in New York, New York.